MIDLOTHIAN, Va., March 10 PARI's LC STAR nebulizer andPRONEB Ultra II compressor are the exclusive delivery devices for InspirePharmaceuticals' (Nasdaq: ISPH) second Phase 3 clinical trial for a ...
Respiratory devicemaker PARI picked up an approval from the FDA for its eRapid nebulizer system, which is the first electronic one to deliver Genentech's cystic fibrosis treatment Pulmozyme. A ...
- ARIKAYCE is the First and Only Therapy Specifically Indicated for the Treatment of Mycobacterium Avium Complex (MAC) Lung Disease in Adult Patients with Limited or No Alternative Treatment Options - ...
STARNBERG, Germany, June 7, 2016 /PRNewswire/ -- PARI Pharma, a company focused on the development of advanced aerosol therapies using eFlow Technology, announces that its proprietary closed eFlow ...
As highlighted in the April issue of Medical Device & Diagnostic Industry magazine, PARI Aerosol Research Institute has been awarded a 2006 Medical Design Excellence Award for eFlow. eFlow is an ...
Sellbyville, DE -- (SBWIRE) -- 06/18/2019-- Pneumatic Nebulizers Market size is set to exceed USD 875 million by 2024; according to a new research report by Global Market Insights. Rising elderly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback